NIH-funded research R21 grant

Understanding how herpes simplex viruses enter human cells

Official title: Capturing HSV entry glycoprotein complexes

Funded at Tufts University Boston · NIH-11117997 · Data updated 2026-11-12

This study is looking at how the herpes viruses get into our cells, so researchers can find new ways to create vaccines and treatments since there aren’t any good options available right now.

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionTufts University Boston
NIH-funded
Lab location1 site (Boston, United States)
Project startFebruary 1, 2025
Project endJanuary 31, 2027
Funding year2025
Award (this year)$236,292
NIH project number1R21AI190726-01
Project IDNIH-11117997 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals who are infected with HSV-1 or HSV-2, particularly those experiencing recurrent outbreaks or complications such as blindness.

Less likely to help

Patients who are not infected with herpes simplex viruses or those who have already developed effective immunity may not benefit from this research.

What this research studies

This research investigates the mechanisms by which herpes simplex viruses (HSV-1 and HSV-2) enter human cells, focusing on the specific glycoprotein complexes involved in the process. The researchers aim to isolate and analyze these glycoprotein complexes using advanced techniques like cryo-electron microscopy. By understanding how these proteins interact and function, the research seeks to identify potential targets for new vaccines and therapies. This work is crucial as current treatments are not curative and there are no available vaccines.

Why it matters

Potential benefit: If successful, this research could lead to the development of effective vaccines and therapies for herpes simplex virus infections.

How similar studies have gone: While there has been significant research on HSV, the specific approach of isolating and analyzing glycoprotein complexes is relatively novel and has not been extensively tested.

Where this research is happening

  • Tufts University Boston
    Boston, United States
    Active

Researchers

  • Principal investigator: Heldwein, Ekaterina — Tufts University Boston
  • Study coordinator: Heldwein, Ekaterina

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.